688177 Bio-Thera Solutions,
- 22.14
- +1.64+8.00%
Bio-Thera Solutions, News
Bio-Thera Solutions' Betanin Gets Marketing Green Light From Chinese Drug Regulator
Bio-Thera Solutions' (SHA:688177) bevibatide citrate injection obtained a drug registration certificate from Chinese drug regulator National Medical Products Administration, according to the company's
Bio-Thera Solutions (688177.SH): TOFIDENCE receives market approval from the European Commission.
Bio-Thera Solutions (688177.SH) announced that its partner, Biogen International GmbH ("Biogen"), has recently received notice from the European Commission that TOFIDENCE (BAT1806, tocilizumab injection) has been approved for marketing by the European Commission for the treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and COVID-19.
Bio-Thera Solutions (688177.SH) received a government subsidy of 41.4193 million yuan.
Bio-Thera Solutions (688177.SH) announced on June 5th that from January 1, 2024 to the date of this announcement, the company has received a cumulative government subsidy of RMB 41,419,300, of which RMB 26,419,300 is related to revenue and RMB 15,000,000 is related to assets.
Bio-Thera Solutions (688177.SH): Therabio and Fanwan Lake plan to reduce their shareholdings by a total of no more than 2% through bulk trading.
On June 4th, Gelunhui reported that Bio-Thera Solutions (688177.SH) announced that Therabio and Wanwan Lake plan to reduce their holdings of the company's shares through block trades due to their own capital arrangement needs, with a total of no more than 8,281,600 shares (including this number), accounting for no more than 2% of the total share capital of the company, under the premise of complying with laws and regulations. The block trades will be conducted within 3 months after 15 trading days from the date of this announcement, and the total number of shares sold during any consecutive 90 days shall not exceed 2% of the company's total share capital. If there are restrictions on the window period for buying and selling stocks during the reduction period, the share reduction will be stopped.
Express News | Bio-Thera Solutions Receives Positive Chmp Opinion for Avzivi® (Bevacizumab), a Biosimilar Referencing Avastin®
Bio-Thera Solutions (688177.SH): Avzivi (bevacizumab injection) received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency.
On June 3, Gelonhui reported that Bio-Thera Solutions (stock code 688177.SH) has recently received a notice from the European Medicines Agency (EMA) that Avzivi (BAT1706, bevacizumab injection) has received positive opinions from the EMA Committee for Medicinal Products for Human Use (CHMP). CHMP recommended that the European Commission approve the launch of Avzivi for the treatment of metastatic colorectal cancer, metastatic breast cancer, non-small cell lung cancer, metastatic renal cell carcinoma, epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer, and metastatic cervical cancer.
Bio-Thera Solutions (SHSE:688177) Is Making Moderate Use Of Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' It's only natural to consider a company's balance sheet wh
Bio-Thera Solutions Grants STADA European Commercialization Rights for BAT2506 Injection
Bio-Thera Solutions (SHA:688177) granted German pharmaceutical company STADA Arzneimittel the exclusive rights to commercialize BAT2506 (golimumab) injection in the European Union, the UK, Switzerland
China Gives Nod to Bio-Thera Solutions' Clinical Trials for Anti-Tumor Drug Combo
China's medical products administrator granted clinical trial approval to Bio-Thera Solutions' (SHA:688177) combination of BAT8008 and BAT7104 for the treatment of advanced solid tumors, according to
Biotech (688177.SH) and STADA sign licensing and commercialization agreement for BAT2506 (golimumab) injection
Biotai (688177.SH) announced that the company and STADA Arzneimittel...
Biotech (688177.SH): BAT8008 in combination with bevacizumab or BAT7104 obtained approval notice for drug clinical trials
Baiaotai (688177.SH) announced that the company recently received from the State Drug Administration (“National Drug Administration...
Bio-Thera Solutions Gets Nod to Trial Tumor Drug Combination
Bio-Thera Solutions (SHA:688177) will conduct clinical trials on a drug combination after receiving approval from China's National Medical Products Administration, the company said in its filing on th
Baiaotai (688177.SH): BAT6005 and BAT1308 injections obtained approval notice for drug clinical trials
On May 24, Ge Longhui (688177.SH) announced that it recently received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, and the company's clinical trial application for the drug BAT6005 combined with BAT1308 injection to treat locally advanced or metastatic solid tumors was approved. At present, the phase I clinical trial of BAT6005 has completed the single-drug dose climbing phase, and the safety is good; early studies of BAT1308 showed positive anti-tumor activity and good safety. Multiple joint administration studies with BAT1308 are ongoing, including B
China Grants Clinical Trial Approval to Bio-Thera's Anti-Tumor Combination Therapy
China's medical products administrator granted Bio-Thera Solutions (SHA:688177) clinical trial authorization for its BAT1308 and BAT8006 combination therapy for advanced solid tumors, according to a F
Biotech (688177.SH): BAT2206 (usinumab) injection marketing license application accepted
On May 8, Ge Longhui (688177.SH) announced that the company recently received the “Notice of Acceptance” approved and issued by the State Drug Administration regarding the marketing license application for the drug usinumab injection (“BAT2206”) under development. BAT2206 is an usinumab injection developed by Biotech in accordance with the guidelines related to bioanalogues of the National Drug Administration, the US FDA, and the European Union EMA. Usinumab is an all-human monoclonal antibody targeting the p40 subunit common to the interleukins IL-12 and IL-23. IL-12 and IL-23 are
Biotech (688177.SH) announced first-quarter results with a net loss of 119 million yuan
Biotech (688177.SH) released its report for the first quarter of 2024. During the reporting period, the company achieved operating income of 1...
Private Companies Among Bio-Thera Solutions, Ltd.'s (SHSE:688177) Largest Stockholders and Were Hit After Last Week's 12% Price Drop
Key Insights The considerable ownership by private companies in Bio-Thera Solutions indicates that they collectively have a greater say in management and business strategy A total of 4 investors hav
Baiaotai (688177.SH): tocilizumab injection obtained drug registration certificate
On April 3, Gelonghui (688177.SH) announced that it has recently received the “Drug Registration Certificate” for tocilizumab injection (trade name: Schruili) approved and issued by the State Drug Administration. Schrelli is a recombinant humanized monoclonal antibody targeting the interleukin-6 receptor (IL-6R). It binds specifically to soluble and membrane-bound IL-6 receptors (sil6r and MIL-6r) and inhibits signal transduction mediated by SIL-6r or MIL-6r.
Baiaotai (688177.SH) plans to sign an energy management agreement for distributed rooftop photovoltaic power plants with Qixi Computer
Baiaotai (688177.SH) announced that the company plans to cooperate with the related party Guangzhou Qixi Computer Co., Ltd. (“Qixi Electronics...
Biotech (688177.SH) announced its 2023 annual results, with a net loss of 395 million yuan, and the loss narrowed
Biotech (688177.SH) released its 2023 annual report. The company's revenue was 705 million yuan, compared with...
Analysis
Price Target
No Data
